While the numbers have been in-line, the company has headroom for better growth, says Surajit Pal, Pharma analyst at Prabhudas Lilladher. Capacity constraints for approved products continue to weigh on Aurobindo.
first published: Aug 24, 2016 12:39 pm
A collection of the most-viewed Moneycontrol videos.

‘Ashoka University Won’t Expand to Other Cities’ | Pramath Raj Sinha & Ashish Dhawan LIVE

Live: Nifty to test 26,000-mark on monthly expiry day | Opening Bell

LIVE: Moneycontrol Mutual Fund Summit 2025 |Bengaluru| Decoding Purpose, Products, Tech

Nifty, Sensex Gain On Easing US–China Trade Tensions, Fed Rate Cut Hopes | Closing Bell
You are already a Moneycontrol Pro user.

